Karapanagiotou et al. showed that serum resistin levels were higher in lung cancer patients compared with healthy controls [25] while Bonaventura et al. showed that higher serum resistin levels were associated with worse overall survival and that combining resistin levels and neutrophil-lymphocyte ratios could predict NIVO response in advanced NSCLC [26]. The gene discussed is RETN; the disease is non-small cell lung carcinoma.